探索实施帕金森病双重任务培训的障碍和教育需求:专业人士的见解
Josefa Domingos1,2, John Dean3, Júlio Belo Fernandes2,4
1Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Center of Expertise for Parkinson and Movement Disorders, Nijmegen, Netherlands.
Frontiers in medicine
|April 22, 2024
概括
医疗保健专业人员面临的挑战是为帕金森病 (PD) 实施双重任务培训. 主要障碍包括时间限制,缺乏创造性想法和缺乏专业知识,突出了针对性教育的需要.
科学领域:
- 神经康复疗法 神经康复疗法
- 运动障碍 运动障碍
- 盟友卫生专业 医疗保健专业
背景情况:
- 双任务训练在改善帕金森病 (PD) 的身体和认知功能方面表现有前途.
- 对于为PD患者提供双重任务培训的专业人员的教育需求和实施障碍的理解有限.
研究的目的:
- 探索医疗保健和运动专业人员的障碍和教育需求,以便将双重任务培训纳入PD患者的实践中.
主要方法:
- 通过社交媒体分发了一项基于网络的调查,以招募与PD患者工作的运动和医疗保健专业人员.
- 该调查收集了有关专业人口统计,培训背景,以及实施双重任务培训的感知挑战和教育要求的数据.
主要成果:
- 185名符合条件的专业人士回答,主要是物理治疗师 (68.1%).
- 发现的主要障碍包括缺乏准备时间,难以获得新想法,不可靠的结果测量工具和缺乏专业知识.
- 专业人士表示需要实践干预示例,战略指导和针对PD症状的定制应用.
结论:
- 专业人士在将双重任务培训整合到帕金森病护理中时遇到重大挑战.
- 知识差距,对创新策略的获取有限以及时间限制是主要障碍.
- 通过有针对性的教育和资源开发来解决这些障碍,对于有效实施至关重要.
相关概念视频
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541


